What a difference a change in seasons makes.

This summer, Kirkland & Ellis found itself caught up in a conflict of interest controversy that simmered around its representation of Teva Pharmaceutical Industries over the Israeli generic drug giant's $40 billion unsolicited bid for Mylan.

These days, however, neither Kirkland nor Teva seems to be feeling the weight of Mylan's previously pointed finger. Teva eventually pulled the plug on its offer for Mylan, instead moving forward with a $40.5 billion buy of the generic drug business of Dublin-based Allergan.